Pancreatic Cancer Research

Journal articleEur J Pharm Sci2018

Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.

Journal
Eur J Pharm Sci
Published
31 January 2018
Citations
16
Type
Article

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

The aim of this evaluation was to characterize the impact of the tumour size (TS) effects driven by the anticancer drug gemcitabine on overall survival (OS) in patients with advanced pancreatic cancer by building and validating a predictive semi-mechanistic joint TS-OS model. TS and OS data were obtained from one phase II and one phase III study where gemcitabine was administered (1000-1250 mg/kg over 30-60 min i.v infusion) as single agent to patients (n = 285) with advanced pancreatic cancer. … Excerpt only: this text is the publisher’s. Read it in full at the source.